

IMPROVE CLINICAL OUTCOMES BY FEEDING EVIVO TO YOUR NICU PATIENTS

Feeding Evivo (activated *B. infantis* EVC001) solves gut dysbiosis in NICU patients.

This hospital NICU study provides clinical evidence that Evivo¹:

Reduces
enteric
inflammation

70%*

of NICU infants fed Evivo
had **reduced enteric
inflammation**

Decreases
antibiotic
exposure

62%

of NICU infants fed Evivo
had **decreased incidence
antibiotic exposure**

Reduces
ARG
abundance

81%

of NICU infants fed Evivo
had **fewer ARGs**


Lower
incidence of
diaper rash

62%

of NICU infants fed Evivo
had **lower incidence of
diaper rash**


*Based on TNF α quantification

Reduced Enteric Inflammation



Fecal calprotectin is 1.5-fold lower in neonates fed Evivo

Decreased Incidence of Antibiotic Exposure



Neonates fed Evivo have decreased incidence of antibiotic exposure

1. Nguyen, M et al. (2021) Frontiers in Pediatrics, 9:618009


New Study in
Frontiers in Pediatrics

RESOLVE GUT DYSBIOSIS AND IMPROVE HEALTH OUTCOMES IN YOUR NICU PATIENTS

Evivo (activated *B. infantis* EVC001) is the **first and only infant probiotic clinically demonstrated to improve the biochemistry of the infant gut**, reducing potential gut pathogens and improving human milk utilization^{1,2}.



Evivo Reduces Pathogenic Bacteria in NICU infants



Escherichia abundance is inversely correlated with *Bifidobacterium* in the NICU.

Establish Evivo as the **Standard of Care** in your NICU

- ✓ Resolve gut dysbiosis
- ✓ Create a protective environment in the infant gut
- ✓ Decrease enteric inflammation

1. Nguyen, M et al. (2021) *Frontiers in Pediatrics*, 9:618009. 2. Frese SA et al. *mSphere*. 2017; 2(6):e00501-17.



Visit [Evivo.com/Professional](https://www.evivo.com/Professional) to learn more about this NICU study and to request a scientific presentation.